7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/23/2013

Company Name Symbol %Change
WESTELL TECH WSTL
6.67%
STEIN MART I SMRT
5.38%
ALLIANCE FIB AFOP
5.21%
DAWSON GEOPH DWSN
4.33%
MARRIOTT VAC VAC
3.27%

Allstate Reinstated at Neutral

by Zacks Equity Research

March 15, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Mar 14, we reiterated our recommendation on Allstate Corp. ( ALL - Analyst Report ) to Outperform based on substantial improvements in its fundamentals, which paves the way for healthy capital deployment.

Why the Retention?

On Feb 6, Allstate reported fourth-quarter 2012 operating earnings per share (EPS) of 59 cents, which significantly exceeded the Zacks Consensus Estimate of a loss of 7 cents. However, EPS lagged the year-ago quarter’s earnings of $1.45 a share. Net revenue climbed 3.8% year over year to $8.55 billion and substantially topped the Zacks Consensus Estimate of $7.26 billion.

Allstate witnessed quite a boost over the last 60 days, signifying noticeable growth ahead. The Zacks Consensus Estimate for 2013 rose 2.4% to $4.62 per share, whereas for 2014, it grew 3.3% to $5.06 per share. Meanwhile, the Most Accurate Estimate for Allstate’s 2013 earnings stands at $4.63, resulting in a positive ESP (read: Zacks Earnings ESP: A Better Method) of +0.22%.

Consequently, with the Zacks Consensus Estimates for both 2013 and 2014 showing steady upward pressure on the stock in the near term, Allstate now has a Zacks Rank #1 (Strong Buy).

What is the cause for the strong positive bias on the company? Strong fourth quarter results despite the huge catastrophe losses, the agency expansions, healthy ratings affirmation, the latest 13.6% dividend increment, expanded share buyback, product restructuring and acquisitions validate Allstate’s long-term stability.

An appreciated investment portfolio also boosts the operating cash flow and liquidity, reflected by an improved operating return on equity (ROE) of 12.4% at 2012-end against 3.8% at 2011-end.

Though the current volatile economy and the catastrophe losses will continue to impact the results in the upcoming quarters, continued synergies are expected from Allstate’s industry-leading position, diversification and pricing discipline. All these factors should augur growth once the markets regain momentum.

Other Stocks to Consider

Apart from Allstate, other stocks that are outperforming in the insurance sector include Aegon NV ( AEG - Snapshot Report ) , XL Group Plc ( XL - Analyst Report ) and Amerisafe Inc. ( AMSF - Analyst Report ) . All these stocks carry a Zacks Rank #1 (Strong Buy).

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.